HALO
HALOZYME THERAPEUTICS, INC.
+1.55 (+1.43%)109.99USD825K成交股數12.5B市值32.2本益比(近四季)7.5股價營收比+47.7%營收年增(近四季)2026-11-02下次財報
財報 SEC XBRL 申報值 · 美元 · 財年於 12 月結束
逐季數字是 10-Q 的單季值;財年第四季 XBRL 只有年度值,這裡用年度減前三季推算。年增率比的是去年同一會計季。
營收與利潤率近 16 季
稀釋 EPS近 16 季 · 美元
現金流近 16 季
股東回饋近 16 季 · 庫藏股與股利
損益表 逐季 · 最新在左 · 小字是年增率
| 科目 | 26Q2 | 26Q1 | 25Q4 | 25Q3 | 25Q2 | 25Q1 | 24Q3 | 24Q2 | 24Q1 | 23Q4 | 23Q3 | 23Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 營收 | 481M+48% | 377M+42% | 452M+56% | 354M+53% | 326M+66% | 265M+15% | 290M+34% | 231M+5% | 196M | 230M | 216M | 221M |
| 營業成本 | 79.2M | 79.2M | 78.8M | 55.2M | 46.4M | 48.4M | 49.4M | 39.6M | 28.3M | 52.3M | 54.8M | 50.1M |
| 毛利 | 402M+44% | 297M+37% | 373M+55% | 299M+56% | 279M+67% | 216M+22% | 241M+49% | 192M+12% | 168M | 178M | 161M | 171M |
| 毛利率 | 83.5% | 79.0% | 82.6% | 84.4% | 85.8% | 81.7% | 83.0% | 82.9% | 85.5% | 77.3% | 74.6% | 77.3% |
| 研發費用 | 27.7M | 25.6M | 31.9M | 17.3M | 17.5M | 14.8M | 18.5M | 21.0M | 19.1M | 21.3M | 17.3M | 19.7M |
| 銷售管理費用 | 57.0M | 57.9M | 77.0M | 46.1M | 41.6M | 42.4M | 41.2M | 35.7M | 35.1M | 37.6M | 35.3M | 38.9M |
| 營業利益 | 288M+42% | 185M+30% | −92.9M-157% | 218M+86% | 202M+112% | 142M+40% | 163M+85% | 117M+24% | 95.5M | 101M | 88.3M | 94.5M |
| 營業利益率 | 59.8% | 49.0% | -20.6% | 61.5% | 62.2% | 53.4% | 56.3% | 50.7% | 48.8% | 43.9% | 40.9% | 42.7% |
| 稅後淨利 | 230M+39% | 150M+27% | −142M-203% | 175M+88% | 165M+115% | 118M+38% | 137M+67% | 93.2M+25% | 76.8M | 85.4M | 81.8M | 74.8M |
| 淨利率 | 47.8% | 39.8% | -31.3% | 49.5% | 50.7% | 44.6% | 47.2% | 40.3% | 39.2% | 37.1% | 37.9% | 33.8% |
| 稀釋 EPS | 1.90+43% | 1.22+31% | -1.13-208% | 1.43+99% | 1.33+122% | 0.93+45% | 1.05+72% | 0.72+29% | 0.60 | 0.64 | 0.61 | 0.56 |
| 稀釋股數 | 121M | 123M | 124M | 122M | 124M | 127M | 130M | 129M | 129M | 134M | 134M | 134M |
資產負債表 期末餘額
| 科目 | 26Q2 | 26Q1 | 25Q4 | 25Q3 | 25Q2 | 25Q1 | 24Q3 | 24Q2 | 24Q1 | 23Q4 | 23Q3 | 23Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 現金與約當現金 | 163M | 310M | 134M | 420M | 61.9M | 176M | 154M | 188M | 165M | 118M | 274M | 221M |
| 應收帳款 | 453M | 458M | 426M | 344M | 315M | 304M | 273M | 210M | 185M | 233M | 214M | 222M |
| 存貨 | 137M | 155M | 176M | 186M | 182M | 165M | 131M | 159M | 169M | 128M | 129M | 132M |
| 總資產 | 2.6B | 2.7B | 2.5B | 2.2B | 2.1B | 2.2B | 2.1B | 2.0B | 1.8B | 1.7B | 1.9B | 1.8B |
| 有息負債 | 1.9B | 1.9B | 2.1B | 800M | 1.5B | 1.5B | 1.5B | 1.5B | 1.5B | 1.5B | 1.5B | 1.5B |
| 總負債 | 2.4B | 2.5B | 2.5B | 1.7B | 1.7B | 1.7B | 1.7B | 1.7B | 1.7B | 1.6B | 1.6B | 1.7B |
| 股東權益 | 144M | 220M | 48.8M | 504M | 333M | 482M | 453M | 289M | 178M | 83.8M | 249M | 151M |
| 負債比 | 94.4% | 91.8% | 98.1% | 77.3% | 83.8% | 78.0% | 78.6% | 85.3% | 90.3% | 95.2% | 86.8% | 91.7% |
| 淨現金(現金 − 有息負債) | −1.8B | −1.6B | −2.0B | −380M | −1.4B | −1.3B | −1.3B | −1.3B | −1.3B | −1.4B | −1.2B | −1.3B |
現金流量表 單季
| 科目 | 26Q2 | 26Q1 | 25Q4 | 25Q3 | 25Q2 | 25Q1 | 24Q3 | 24Q2 | 24Q1 | 23Q4 | 23Q3 | 23Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 營業現金流 | – | 180M+17% | – | – | – | 154M | – | – | 129M | – | – | – |
| 資本支出 | – | 3.7M | – | – | – | 950K | – | – | 3.5M | – | – | – |
| 自由現金流 | – | 176M+15% | – | – | – | 153M | – | – | 126M | – | – | – |
| 折舊攤銷 | 4.5M | 4.2M | 3.3M | 2.7M | 2.7M | 2.7M | 2.6M | 2.6M | 2.4M | 3.0M | 2.7M | 2.8M |
| 買回庫藏股 | – | – | – | – | – | – | – | – | 0.00 | – | – | – |
| 現金股利 | – | – | – | – | – | – | – | – | – | – | – | – |
| 自由現金流率 | – | 46.8% | – | – | – | 57.9% | – | – | 64.3% | – | – | – |
營收拆解 2025 年度 10-K 的分部揭露 · 年增對前一年度
產品／服務2025 年度 · 1.1B
| Royalty | 868M | 81.2% | +52.0% |
|---|---|---|---|
| Salesbasedmilestone | 70.0M | 6.5% | +133.3% |
| Device Partnered Products | 48.8M | 4.6% | -3.4% |
| Event Based Development And Regulatory Milestone And Other Fees | 47.0M | 4.4% | -35.2% |
| Upfront Fees | 18.5M | 1.7% | -31.6% |
| Device Licensing And Development | 16.9M | 1.6% | +48.6% |
| 產品 小計 | 376M | 35.2% | +24.0% |
| Proprietary Products Sales 小計 | 195M | 18.2% | +16.8% |
| Collaborative Agreements 小計 | 152M | 14.2% | +8.2% |
| Bulk R Hu PH20 小計 | 133M | 12.4% | +54.1% |
各維度的加總不一定等於合併營收:分部有時含內部交易、地區有時只揭露主要國家。挑的是加總最接近合併營收的那個標籤。
年度 10-K
| 財年 | 營收 | 年增 | 稅後淨利 | 淨利率 | 稀釋 EPS | 自由現金流 |
|---|---|---|---|---|---|---|
| FY2025 | 1.4B | +37.6% | 317M | 22.7% | 2.56 | 645M |
| FY2024 | 1.0B | +22.4% | 444M | 43.7% | 3.43 | 468M |
| FY2023 | 829M | +25.6% | 282M | 34.0% | 2.10 | 373M |
| FY2022 | 660M | +48.9% | 202M | 30.6% | 1.44 | 235M |
| FY2021 | 443M | +65.7% | 403M | 90.8% | 2.74 | 298M |
| FY2020 | 268M | +36.5% | 129M | 48.2% | 0.91 | 53.0M |
| FY2019 | 196M | +29.1% | −72.2M | -36.9% | -0.50 | −89.5M |
| FY2018 | 152M | – | −80.3M | -52.9% | -0.56 | −54.2M |